application) A growing number of hematological diseases can be diagnosed before birth. In some cases, early treatment may benefit the health and survival of the fetus. Either in utero stem cell transplantation (IUT) or fetal gene therapy may treat diseases such as the hemaglobinopathies. This application aims to determine the best method for the introduction of genes into fetal hematopoietic stem cells (HSCs). Fetal HSCs are more proliferative than their adult counterparts and are, therefore, hypothesized to be more susceptible to transduction by retroviral vectors based on murine leukemia virus or human immunodeficiency virus. IUT offers another means of curing a number of hematological diseases by generating a state of hematopoietic chimerism. However, in the absence of any advantage for the donor HSCs, the levels of chimerism that can be achieved by IUT are low. This limits the use of this therapy to very few diseases.
Our aim i s to extend the use of IUT to the treatment of diseases, such as thalassemia and sickle cell anemia, by engineering HSCs to have a proliferative advantage over normal HSCs. This application will test if introduction of the erythropoietin receptor (EpoR) into HSCs will render these altered cells responsive to erythropoietin (EPO). This will in turn result in the altered HSCs and their progeny having a proliferative advantage over normal progenitors. Truncated forms of EpoR (tEpoR) will also be tested. These tEpoR, having deletions in the negative regulatory region of their cytoplasmic domains, deliver stronger proliferative signals than EpoR. The effects of introducing the EpoR genes on the proliferation and differentiation of HSCs and their progenitor progeny will be determined using various in vitro culture systems. It is hypothesized that ectopic expression of either EpoR or tEpoR will confer the ability of HSCs and early progenitors to proliferate in response to EPO with minimal effect on the differentiation program of these cells. To test if ectopic EpoR or tEpoR expression on HSCs can make these cells more competitive than their normal counterparts, modified HSCs will be tested against control HSCs in a mouse model of human hematopoiesis. The ability of HSCs expressing ectopic EpoR to engraft bone marrow after no or only minimal cytoablation will also be tested. These in vivo experiments will further determine if making HSCs responsive to EPO will have any detrimental effect on the long‑term reconstituting‑ and multilineage‑ potential of HSCs. A positive outcome from the proposed studies would aid in developing treatments for hemoglobinopathies based on generating hematopoietic allochimerism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Scientist Development Award - Research & Training (K01)
Project #
1K01DK059301-01
Application #
6317592
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Bishop, Terry Rogers
Project Start
2001-09-01
Project End
2004-08-31
Budget Start
2001-09-01
Budget End
2002-08-31
Support Year
1
Fiscal Year
2001
Total Cost
$84,780
Indirect Cost
Name
University of California San Francisco
Department
Surgery
Type
Schools of Medicine
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Muench, Marcus O; Chen, Jeng-Chang; Beyer, Ashley I et al. (2011) Cellular therapies supplement: the peritoneum as an ectopic site of hematopoiesis following in utero transplantation. Transfusion 51 Suppl 4:106S-117S
Chen, Jeng-Chang; Chang, Ming-Ling; Muench, Marcus O (2008) Persistence of allografts in the peritoneal cavity after prenatal transplantation in mice. Transfusion 48:553-60
Muench, Marcus O; Ohkubo, Tatsuo; Smith, Clayton A et al. (2006) Maintenance of proliferative capacity and retroviral transduction efficiency of human fetal CD38(-)/CD34(++) stem cells. Stem Cells Dev 15:97-108
Ishimoto, Hitoshi; Muench, Marcus O; Higuchi, Takayuki et al. (2006) Midkine, a heparin-binding growth factor, selectively stimulates proliferation of definitive zone cells of the human fetal adrenal gland. J Clin Endocrinol Metab 91:4050-6
Muench, M O (2005) In utero transplantation: baby steps towards an effective therapy. Bone Marrow Transplant 35:537-47
Chen, Jeng-Chang; Chang, Ming-Ling; Lee, Hanmin et al. (2005) Prevention of graft rejection by donor type II CD8(+) T cells (Tc2 cells) is not sufficient to improve engraftment in fetal transplantation. Fetal Diagn Ther 20:35-43
Muench, Marcus O; Barcena, Alicia (2004) Megakaryocyte growth and development factor is a potent growth factor for primitive hematopoietic progenitors in the human fetus. Pediatr Res 55:1050-6
Suskind, David L; Muench, Marcus O (2004) Searching for common stem cells of the hepatic and hematopoietic systems in the human fetal liver: CD34+ cytokeratin 7/8+ cells express markers for stellate cells. J Hepatol 40:261-8
Chen, Jeng-Chang; Chang, Ming-Ling; Lee, Hanmin et al. (2004) Haploidentical donor T cells fail to facilitate engraftment but lessen the immune response of host T cells in murine fetal transplantation. Br J Haematol 126:377-84
Suskind, David L; Rosenthal, Philip; Heyman, Melvin B et al. (2004) Maternal microchimerism in the livers of patients with biliary atresia. BMC Gastroenterol 4:14

Showing the most recent 10 out of 14 publications